|
|
|
|
|
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care Vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
/ Not yet recruiting临床2期IIT A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
A Phase II, Single Arm, Open Label, Efficacy and Safety Study of NEOD001 in Subjects with Light Chain (AL) Amyloidosis with Hepatic Involvement - ---
100 项与 SAA1 x 淀粉样蛋白轻链 相关的临床结果
100 项与 SAA1 x 淀粉样蛋白轻链 相关的转化医学
0 项与 SAA1 x 淀粉样蛋白轻链 相关的专利（医药）
